Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-03T13:20:46.876Z Has data issue: false hasContentIssue false

Long-acting Paliperidone Palmitate treatment in an Ekbom’s Syndrome secondary to Lewy Body Dementia: A case report

Published online by Cambridge University Press:  01 September 2022

L. Orsolini
Affiliation:
Unit of Clinical Psychiatry, Department Of Neurosciences/dimsc, Polytechnic University Of Marche, Ancona, Italy
D. Corona*
Affiliation:
Unit of Clinical Psychiatry, Department Of Neurosciences/dimsc, Polytechnic University Of Marche, Ancona, Italy
M. Giordani
Affiliation:
Unit of Clinical Psychiatry, Department Of Neurosciences/dimsc, Polytechnic University Of Marche, Ancona, Italy
V. Salvi
Affiliation:
Unit of Clinical Psychiatry, Department Of Neurosciences/dimsc, Polytechnic University Of Marche, Ancona, Italy
U. Volpe
Affiliation:
Unit of Clinical Psychiatry, Department Of Neurosciences/dimsc, Polytechnic University Of Marche, Ancona, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Ekbom Syndrome (ES) is a condition characterized by the fixed, delusional belief that one’s body is infested by parasites or other vermin, in absence of supporting clinical evidence. Literature suggests antipsychotic treatment for the management of behavioural and psychotic symptomatology, long-acting-injectable (LAI) antipsychotics for poor compliance.

Objectives

A case report of a 70-year-old woman with an ES diagnosis treated with LAI palmitate paliperidone was followed-up for an 8-months period, resulting in a confirmed diagnosis of secondary ES to Lewy Body Dementia (LBD).

Methods

Patient was admitted to the local psychiatry ward presenting with new-onset visual and tactile hallucinations and social withdrawal. She was diagnosed with ES in a context of executive functions impairment. She was initially treated with risperidone, then switched to LAI Paliperidone due to poor compliance. Subsequently she was monitored monthly for 8 months by administering PANSS, MOCA, GAF, BPRS, PSP, complete neurocognitive assessment and neuroimaging studies

Results

After 8 months a progressive cognitive deterioration and worsening of motor impairment confirmed a secondary ES to a LBD. Meanwhile, a significant reduction of psychotic symptomatology (delusions and somatic hallucinations) was observed at BPRS and PANSS positive scale, even after treatment discontinuation due to the onset of extrapyramidal symptoms of the underlying condition.

Conclusions

LAI Paliperidone treatment induced a complete remission of psychotic symptoms, with no relapse even after discontinuation of treatment. Moreover, close observation during follow-up allowed early diagnosis of LBD, which has been associated with a more favorable course.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.